Orrick Advises Tiziana Life Sciences on Nasdaq Registered Direct Offering of Up to Approximately $17.6 Million

Orrick represented Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana") on its registered direct offering of 6.4 million new ordinary shares at $1.25 each, for gross proceeds of approximately $8 million.

For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including July 16, 2026 (when the warrants expire), resulting in additional gross proceeds of up to approximately $9.6 million.

The offering is expected to close on January 16, 2026, subject to the satisfaction of customary closing conditions.

THE COMPANY

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

Tiziana's innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.

Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date.

Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

THE IMPACT

Tiziana noted that the proceeds from this offering enable it to complete its Phase 2 non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA) clinical trials, and achieve top line data readouts in both trials.

THE TEAM

The Orrick team was led by Ed Lukins, supported by Edward Dyson and Abigail Parkin.

LEARN MORE

• Tiziana news announcement
• Read More Orrick Client Results